Moderna develops messenger RNA (mRNA) therapeutics and vaccines, self-described as a pioneer in the field.

Moderna

Domain Not Resolving

DNSSEC

Google Maps

WordPress

LetsEncrypt

US Privacy User Signal Mechanism

reCAPTCHA

Cloudflare CDN

IPv6

Cloudflare

Sr. Consultant - Global MedEd Content Owner & Beta Communities Owner

Caitlin Monney

VP, Associate General Counsel, Intellectual Property

Darrell Fontenot

Chief Financial Officer

David Meline

Deviation Writer

David Morales

Director, Business Process Owner (AP/T&E)

Heather Barber

President Strategic Partnerships and Enterprise Expansion

Juan Andres

Sr. Director, Head of CDO Strategic Operations

Kaleen Childers

Co-Founder

Kenneth Chien

Marketing and Product

Krystopher Berg

Talent Acquisition Manager, Corporate Functions & Digital

Kyle Greenleaf

Robert Langer

Peter Hutt

Paul Sagan

Moncef Slaoui

Israel Ruiz

Stephen Berenson

Stephane Bancel

Elizabeth Nabel

Noubar Afeyan

Chairman & Co-Founder

Stephen Hoge

President

President and Founding CEO

Kristian Link

Associate Director, Analytical Development

Tatiana Novobrantseva

Chief Scientific Officer, Immuno-Oncology Research

Timothy A. Springer

Eric Ma

Principal Data Scientist

Senior Vice President Technical Development, Manufacturing and Quality

Metagenomi uses metagenomics and machine learning to discover novel genome editing systems for therapeutics development.

Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.

Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.

Seed Stage Investors with Investments in Massachusetts

Private Equity Funded Companies (Top 10K)

New England Companies With More Than 10 Employees (Top 10K)

United States Companies With More Than 500 Employees (Top 10K)

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. 

Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. 

Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

U.S. Department of Health & Human Services

Grant - Moderna

Blackstone Life Sciences

Post-IPO Equity - Moderna

DFO Management

Biomedical Advanced Research and Development Authority (BARDA)

Merck

Series H - Moderna

Series G - Moderna

AstraZeneca

Series F - Moderna

Cambridge

Massachusetts

United States

North America

MGX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In MGX To Contact Him Directly To Discuss Their Options

North American Morning Briefing : Russia's Nuclear -2-

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi

Moderna initiated with neutral view at Berenberg, here's why

Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone

HSBC gets more bullish on Moderna, upgrades shares

Scientists fear what’s next for public health if RFK Jr. is allowed to ‘go wild’

Here are Monday's biggest analyst calls: Nvidia, Netflix, Tesla, Roku, Moderna, CVS, Alphabet, Robinhood and more

Stocks making the biggest moves midday: Moderna, Roku, CVS Health, Robinhood and more

Moderna's decline on RFK Jr's appointment makes an "attractive entry point": Piper Sandler

A COVID-19 vaccine using mRNA technology, approved for use in various age groups and targeting specific virus variants.

An mRNA-based vaccine developed to prevent COVID-19, approved by the FDA for use in 2024-2025.

A next-generation COVID-19 vaccine designed for storage at 2-5 ºC, currently in Phase 3 trials.

A next-generation COVID-19 vaccine designed for easier storage and distribution, currently in Phase 3 trials.

An mRNA-based flu vaccine in Phase 3 trials, aimed at providing protection against influenza.

An mRNA-based flu vaccine in Phase 3 trials aimed at preventing influenza.

South Korea

Asia

Japan

Canada

United Kingdom

Europe

HTML5

DigiCert

jQuery

Modernizr

Wordpress

Comodo PositiveSSL Certificates

Office 365

Microsoft Outlook

F5 NGINX

Amazon EC2

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 25, 2024 9:51 AM	ab41f912
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 26, 2024 2:45 AM	9e0b65ef
company summary	general
signals	general	Sep 25, 2024 9:51 AM	cb9ff681
crunchbase trigger	general	Nov 22, 2024 7:44 AM	8a79b324
crunchbase profile	general	Nov 22, 2024 10:46 AM	c937c274
li profile	general
translate crunchbase fundingrounds	general	Nov 22, 2024 2:25 PM	ee8b32c2
peers	general	Sep 25, 2024 9:51 AM	c134cf1f
news basic	general	Sep 25, 2024 9:51 AM	50d123ae
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

MODE

COM:MODERNA

Moderna